50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#5

CJC-1295

Growth HormoneCJC-1295 DACCJC-1295 without DACModified GRF 1-29Mod GRF

A synthetic growth hormone-releasing hormone (GHRH) analog that stimulates pituitary growth hormone secretion, available in two forms with different duration profiles.

Share:

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a natural hormone produced by the hypothalamus that stimulates the pituitary gland to release growth hormone. The peptide was developed to overcome the very short half-life of natural GHRH (which lasts only minutes in the bloodstream) by incorporating amino acid modifications that resist enzymatic degradation.

CJC-1295 exists in two primary forms. The version with Drug Affinity Complex (DAC) binds to albumin in the blood, extending its half-life to approximately 6-8 days. This allows for less frequent dosing but produces a sustained, non-pulsatile elevation of growth hormone levels. The version without DAC (sometimes called Modified GRF 1-29 or Mod GRF) has a shorter half-life of approximately 30 minutes, which more closely mimics the body's natural pulsatile release pattern of growth hormone when combined with a growth hormone secretagogue like Ipamorelin.

Clinical research on CJC-1295 with DAC showed it could increase growth hormone and IGF-1 levels significantly. In a study of healthy adults aged 21-61, CJC-1295 with DAC produced dose-dependent increases in mean growth hormone levels of 2 to 10-fold above baseline, with IGF-1 levels increasing by 1.5 to 3-fold. These elevations were sustained for up to 6 days following a single injection.

The peptide has gained significant popularity in the anti-aging and performance optimization communities, often used in combination with Ipamorelin (the "CJC/Ipa" stack). This combination is considered by many practitioners to be one of the more conservative approaches to growth hormone optimization, as it works through the body's own pituitary gland rather than providing exogenous growth hormone directly. However, long-term safety data remains limited, and manipulation of the growth hormone axis carries inherent risks.

Research Uses & Applications

  • Stimulating natural growth hormone secretion from the pituitary gland
  • Anti-aging protocols aimed at optimizing growth hormone and IGF-1 levels
  • Supporting body composition improvements including fat loss and lean mass preservation
  • Investigated for improving sleep quality through growth hormone pulse optimization
  • Research into recovery enhancement and tissue repair via growth hormone elevation
  • Studied in combination with GHRP peptides for synergistic growth hormone release

Key Research Findings

  • Single doses of CJC-1295 DAC increased mean GH levels 2 to 10-fold for 6 or more days and IGF-1 levels 1.5 to 3-fold for 9-11 days in healthy adults (JCEM, 2006).
  • Multiple doses produced sustained GH and IGF-1 elevation without desensitization of the GH axis in short-term studies.
  • The modified GRF 1-29 form demonstrated synergistic GH release when combined with GHRP-type peptides in clinical research.
  • No serious adverse events were reported in early phase clinical trials at therapeutic doses.
  • Research indicated preserved pulsatile GH secretion pattern with the non-DAC version, which may be more physiologically favorable.

Risks & Side Effects

  • Potential side effects include water retention, tingling or numbness in extremities, and fatigue.
  • Long-term effects of sustained GH/IGF-1 elevation are not well characterized and may carry risks similar to exogenous GH use.
  • Theoretical concern about promoting growth of undiagnosed tumors through IGF-1 elevation.
  • Injection site reactions including redness, swelling, and irritation.
  • Risk of pituitary desensitization with prolonged use, particularly with the DAC version.

Administration

CJC-1295 with DAC is typically administered via subcutaneous injection at 1-2 mg once or twice weekly. CJC-1295 without DAC (Mod GRF 1-29) is usually dosed at 100-300 mcg per injection, often 1-3 times daily, frequently combined with a GHRP such as Ipamorelin. Injections are commonly taken before bed or in the morning on an empty stomach to align with natural GH release patterns.

Legal Status

CJC-1295 is not FDA-approved for any medical use. It is available as a research chemical and through some compounding pharmacies. It is banned by WADA for athletic competition. It exists in a regulatory gray area in many countries, legally sold for research purposes but not approved for human administration.

Frequently Asked Questions

What is CJC-1295?

A synthetic growth hormone-releasing hormone (GHRH) analog that stimulates pituitary growth hormone secretion, available in two forms with different duration profiles.

What are the main uses of CJC-1295?

The primary research applications of CJC-1295 include: Stimulating natural growth hormone secretion from the pituitary gland; Anti-aging protocols aimed at optimizing growth hormone and IGF-1 levels; Supporting body composition improvements including fat loss and lean mass preservation; Investigated for improving sleep quality through growth hormone pulse optimization; Research into recovery enhancement and tissue repair via growth hormone elevation; Studied in combination with GHRP peptides for synergistic growth hormone release.

What are the risks and side effects of CJC-1295?

Documented risks and side effects include: Potential side effects include water retention, tingling or numbness in extremities, and fatigue.; Long-term effects of sustained GH/IGF-1 elevation are not well characterized and may carry risks similar to exogenous GH use.; Theoretical concern about promoting growth of undiagnosed tumors through IGF-1 elevation.; Injection site reactions including redness, swelling, and irritation.; Risk of pituitary desensitization with prolonged use, particularly with the DAC version.. Always consult a healthcare professional before considering any peptide.

Is CJC-1295 legal?

CJC-1295 is not FDA-approved for any medical use. It is available as a research chemical and through some compounding pharmacies. It is banned by WADA for athletic competition. It exists in a regulatory gray area in many countries, legally sold for research purposes but not approved for human administration.

How is CJC-1295 administered?

CJC-1295 with DAC is typically administered via subcutaneous injection at 1-2 mg once or twice weekly. CJC-1295 without DAC (Mod GRF 1-29) is usually dosed at 100-300 mcg per injection, often 1-3 times daily, frequently combined with a GHRP such as Ipamorelin. Injections are commonly taken before bed or in the morning on an empty stomach to align with natural GH release patterns.

Related Peptides

#6

Ipamorelin

Growth Hormone

#11

Sermorelin

Growth Hormone

#12

Tesamorelin

Growth Hormone

#13

GHRP-6

Growth Hormone

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #4 TB-500#6 Ipamorelin →